In the recent years, ischemic brain injury related to embolization after transcatheter aortic valve replacement (TAVR) has received increased attention as new embolic protection strategies emerged to protect the brain. Diverse cerebral protection devices have been developed to reduce cerebral embolization during TAVR. These devices work through various mechanisms and are in different stages of clinical translation. This review provides the evidence-based review of peri-procedural stroke prevention during TAVR and summarizes currently available cerebral embolic protection devices. Global TAVR volumes are deemed to reach as much as 300 000 annually, including a substantial group of low operative risk patients in the upcoming years.
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| BACKGROUND
Transcatheter aortic valve replacement (TAVR) has evolved as an alternative treatment option for patients with symptomatic severe aortic valve stenosis predicted with high or prohibitive surgery risk. 1, 2 This indication relates both to high, and more recently, intermediaterisk patients after it continued to expand with the PARTNER II and SURTAVI trials showing non-inferiority of TAVR comparing to surgery.
Global TAVR volumes are deemed to reach as much as 300 000 annually, including a substantial group of low operative risk patients in the upcoming years. 3, 4 Despite the new-generation TAVR devices and increased operator experience, the risk of cerebrovascular events remains non-negligible and varies from 2.7% to 5.5% at 30 days. 3, 5, 6 Major cerebral embolic events during TAVR have been identified as an independent predictor of morbidity and mortality. 7 Besides, the majority of patients undergoing TAVR have new-onset, silent brain lesions detected by post-procedural diffusion-weighted magnetic resonance imaging (DW-MRI). 8 These clinically silent brain lesions can be associated with increased risk of dementia and a steeper decline in cognitive function. 9 
| Ischemic brain injury
Since TAVR became accepted therapeutic option for treatment of aortic stenosis, stroke has been a feared and devastating periprocedural complication. Despite the rapid evolution of this technology, lower-profile devices, and increased operator experience, recent studies have raised concerns about adverse cerebrovascular event rates in patients undergoing TAVR. 3, 5 However, stroke frequency is highly dependent on the definition, varying in classification, ascertainment, and thresholds for detecting sub-clinical events, thus often underdiagnosed and underreported in TAVR. 10 Self-reported stroke rates without prospective neurological evaluation likely underestimate true numbers and range from 9% up to 29% when neuroimaging is performed.
11,12
A cerebrovascular event (CVE) after TAVR has been identified as an independent predictor of increased mortality and morbidity during follow-up, as well as a strong impact on life quality, impairing cognitive function and daily abilities. 13, 14 Early experience with transcranial Doppler, post-procedural MRI, and histopathology studies suggested cerebral embolism in the vast majority of TAVR procedures and revealed that ischemic brain lesions occur frequently during balloon valvuloplasty, valve positioning, and valve deployment. 15, 16 TAVR source of cerebral emboli is multiple in origin and includes friable aorta, heavily calcified aortic arch and stenotic valve. These areas strictly correspond with the manipulations during pre-, post-dilatation and implantation itself, in particular in case of repositioning. 17 Over the last few years the totality of evidence concluded from several cerebral embolic protection studies with TAVR have shown consistent device safety and improvement in clinical outcomes and neuroimaging findings compared to control subjects. 11, 12, 18 In this article, we sought to emphasize the importance of stroke prevention during TAVR and expose all currently available cerebral embolic protection devices.
| CEREBRAL PROTECTION SYSTEMS
Numerous devices have been developed to minimize procedural embolization during TAVR (Table 1) . Not only these vary in design, but also feature low-profile access, especially with the next generation systems. The most desirable feature of such a device is the coverage of the ostia of three large branches of the aortic arch, procedural stability of the device, filter capabilities, the ability to preserve the calcified and delicate wall of the aortic arch and full perimeter coverage. Therefore, most of the designs aim to provide maximum coverage of the aortic arch (the brachiocephalic, the left common carotid and the left subclavian artery- Figure 1 ), which intuitively is the answer for best brain protection.
| Sentinel® cerebral embolic protection system (Boston Scientific)
The Sentinel Cerebral Protection System (CPS) consists of two filter baskets within a single 6 F delivery catheter placed percutaneously from the right radial (preferred) or brachial artery over a 0.014-inch guide-wire (Figures 2 and 3 The stroke rates, however, were similar between patients randomized to the embolic filter and those in the control group, although the studies were underpowered for clinical outcomes. 12, 18 In 2017 the Sentinel CPS was evaluated in a multi-center, singleblinded RCT-the SENTINEL study, in which 363 patients undergoing TAVR were randomized to cerebral protection or no protection, with further randomization to safety follow-up or MRI and neurocognitive examination. The device was associated with a favorable safety profile and in almost every case (99%) embolic debris was captured. The incidence of stroke at 30 days, although statistically insignificant, was reduced by as much as 39% (9.1% in the control group and 5.6% in the protected group; P = 0.25). Reduction in new lesion volume on MRI was numerically lower, but not statistically different (P = 0.33). However, after adjusting for baseline lesion volume and valve type, there was a considerable reduction in new lesion volume in protected cerebral territories with CPS (P = 0.02).
Furthermore, the efficacy appeared to be attenuated in patients receiving the Sapien S3 valve. This correlation could be a result of lower rates of embolization with this device due to smaller sheath sizes and lack of routine predilatation. 19 Therefore, another multicenter trial is set to reevaluate the cerebral protection on MRI findings in a four-armed study demonstrated a significantly lower rate of death and stroke for patients undergoing transfemoral TAVR with the Sentinel CPS compared to unprotected TAVR. In contrast to the SENTINEL Trial, the primary endpoint was defined earlier within 7 days, which covers the periprocedural events. 23 The current-generation Sentinel CPS offers filter protection to three of the four major arterial conduits to the brain, leaving the left vertebral artery unprotected. In general, the left vertebral artery is more dominant than the right vertebral artery and therefore has a larger vascular territory. 24 In a small study on eleven patients the left vertebral filter could be deployed in nine cases and it contained debris in an equal amount of patients as the Sentinel filters. The size of the captured particles was similar between all filters indicating that the left vertebral artery is an important entry route for debris to the brain during TAVR. 25 Besides the partial protection issue, the fact worth mentioning is that there is only one size of filter available. Therefore, complete sealing of the intended vessels after deployment of the proximal and distal filter might not be achieved in all aortic anatomies. Hence, nextgeneration embolic protection devices are developed to demonstrate different strategies to address these challenges. To date, more than 11 000 patients have benefited from the use of the Sentinel CPS during their cardiovascular procedures. 
CT angiography is not only used to determine the aortic annulus and access route, but it is also helpful to evaluate the anatomy of the aortic arch and the supra-aortic vessels. Understanding the anatomy (eg, a bovine anatomy), is the key to a successful deployment of CEPs.
Furthermore, measuring the diameter of the supra-aortic vessels is necessary because the proximal and distal filters of the system are designed to accommodate within a brachiocephalic trunk of 9-15 mm and a common carotid of >3 mm, respectively. In particular, fusion imaging of CTA-derived 3D anatomical models and live X-ray may be helpful to improve deployment and safe contrast dye. 26 Regarding the access for the Sentinel CPS, a puncture of the right radial artery becomes necessary. This might be sometimes difficult, in particular advancing the wire derived from the puncture set in calcified arteries. In those cases, it might be helpful to use a regular 0.014 coronary wire to facilitate access. Make sure to have an activated clotting time of 250-300 s before placing any CEPs.
Typically, a left anterior oblique (LAO) projection is used to deploy the CEPs. In particular, the placement of the Sentinel CPS should be performed in this view to place the filters in the correct anatomic position. However, also the deflector systems are positioned in this view to see the aortic arch in its complete length.
During the procedure, interaction and manipulation with the CEPs should be limited to avoid displacement and abrasion of plaques by the CEPs itself. When using the Sentinel CPS, this should not be a problem since only less material is placed in the arch, but it becomes an issue in the deflector systems.
Make sure to remove the system before administering any heparin reversal, for example, protamine. Retrieval of any CEPs should be smooth without too much manipulation to avoid any loss of captured debris.
| TriGuard 3™ embolic deflection device (Venus Medtech, Inc.)
TriGuard 3 is the next generation embolic deflector system from Keystone Heart (now Venus Medtech) designed to better provide three vessel coverage in most anatomies, with less interference with TAVR delivery systems and other heart procedure devices compared to the previous generation TriGuard. It features a larger filter area with a smaller mesh pore size at the same time (Figure 4) . TriGuard 3 incorporates an over the wire design via a 6 F femoral sheath, thereby eliminating the need for a third puncture site.
To evaluate the safety and effectiveness of the previous generation, the TriGuard underwent three prospective and comparable clinical studies of patients undergoing TAVR in the US and Europe, which demonstrated reduced (insignificantly) stroke rates, as well as reduced total lesion volume for patients with complete coverage of all cerebral branches compared to those who were unprotected. 11, 27, 28 These results were based on a pooled analysis of these trials with a total of 142 patients undergoing TAVI with the TriGuard. 29 All patients enrolled in the current REFLECT study designed to assess the safety and efficacy of the second-generation TriGuard HDH embolic deflection device will continue to be evaluated post-procedure and the results will remain blinded. The next-generation TriGuard 3 will be evaluated in the phase 2 of the REFLECT TRIAL, which is expected to complete the enrollment in early 2019. European Union with end-points focused on safety and performance for the system. Currently, the Point-Guard is not commercially available and is an investigational device for investigational use only.
| ProtEmbo® cerebral protection system (Protembis GmbH)
This device is designed to protect all 3 supraaortic vessels by deflecting potentially embolic debris downstream. The low-profile design should allow relatively easy delivery by radial access and it is the only available protection device for TAVR using left radial artery ( Figure 6 ). This avoids interference with TAVR and manoeuvring among the carotid arteries, which among elderly patients can be heavily calcified. 30 After reaching the aortic arch the guiding sheath is placed in the center of the arch and the system is deployed.
Radiopaque markers on the device might help the physician to control its position across the orifices of the great side branches of the aorta.
The heparin coated mesh features much smaller pores than all of the other compared here systems (60 µm) and therefore it gives the potential to protect the brain from smaller in size microparticles of debris. The device is also applicable for surgery and other cardiac interventions such as LAAC and mitral valve repair therapies.
The ongoing PROTEMBO SF Trial (NCT03325283) is set to demonstrate the safety and feasibility of the ProtEmbo® System when used to provide embolic protection during TAVR.
| Emblok™ embolic protection system (Innovative Cardiovascular Solutions, LLC.)
Emblok EPS is intended to provide complete cerebral protection as well as abdominal and peripheral vasculature during valve implantation and other left-sided heart procedures ( Figure 7 ). The entire system allows both embolic filter and pigtail catheter to be advanced simultaneously through a single femoral puncture site. The device incorporates an integrated 4 F radiopaque pigtail catheter, which provides the physician with constant visualization, thus should recently presented the Captis™ Embolic Protection System-a device constructed out of the filter-covered collapsible frame and filter pockets. It is designed to provide "full body embolic protection" by deflecting embolic particles away from the aortic arch and diverting them to the capturing pockets of the device away from renal arteries.
While the attempts to reduce stroke rates are promising, the role of an embolic factor in the pathogenesis of acute kidney injury and its prevention still require more detailed investigations. 32 The Emboliner™ Embolic Protection Catheter (Emboline, Inc.) ( Figure 8 ) is yet another CEP system which represents the idea of complete cerebral and peripheral protection. The main expectations among the population with severe aortic stenosis with respect to treatment, except for the reducing symptoms and staying alive, are to maintain the ability to do specific activities and stay independent, in that matter avoiding strokes. This life-altering disability is particularly devastating in elderly patients who describe it as "worse than death," whereas the younger group is more concerned about mortality, mental acuity and rapid return to normal quality life. (Table 2) . 3, 5, 6, 35 On the other hand, the evaluation of embolic protection during SAVR have shown a substantial number of debris captured in most patients with embolic protection device, without significant reduction in silent or clinical stroke at either 7 or 30 days. 36 As many as 625 patients have been randomized across several clinical trials evaluating cerebral protection during TAVR. 11, 12, 18, 19, 37 Because of the low study size, thus lack of statistical significance, none of them demonstrated a statistically significant reduction in stroke at 30 days, yet they all reported fewer 
. 38 However, this meta-analysis is underreported in the timing of stroke given that peri-procedural stroke occurs mostly within the first 48 h ( Figure 9) ; the longer follow-up period allows cofounders such as atrial fibrillation to influence the results. 39 Furthermore, Seeger et al demonstrated in a prospective all-comers TAVR trial a significant reduction in death or stroke at 7 days in patients subjected to TAVR with the Sentinel CPS compared to the unprotected group. The study included the largest number of patients undergoing emboli-protected TAVR. 23 These findings suggest that embolic protection may be a clinically relevant adjunctive strategy in patients undergoing TAVR.
According to a meta-analysis presented by Luca Testa (IRCSS Policlinico San Donato, Milan, Italy) at EuroPCR 2018, the use of embolic protection appears to reduce the 30-day risk of stroke but do not affect 30-day mortality. Overall, the available data do not support the routine use of embolic protection devices. Instead, they should be considered in selected patients who are at high risk of embolization from the aortic valve, root, and arch. Indeed, there appear to be differences in the size and number of captured tissue particles, with the largest particles observed among patients treated with balloon-expandable devices. 40 Nonetheless, there are no currently known predictors of which TAVR patients are at a higher risk for stroke.
| CONCLUSIONS
Peri-procedural stroke during TAVR has been identified as an independent predictor of morbidity and mortality. The totality of evidence suggests that the use of CEP in TAVR has shown consistent device safety and a significant reduction in death or stroke compared to control subjects, however, given the substantial limitations of the 
